Evidence map›Paper›PMID 42649945›Full record

ArticleCancers2026

Development and Broad Application of a Double Drop-Off ddPCR Assay for Simultaneous Detection of Four

Eleni Thanou, Nikos Gavalas, Eleni Kabrani, Foteini Grigoriou, Anna Konstantinou, Vasiliki Malamatini, Christina Chourdaki Peristeri, Evi Lianidou, Aristotelis Bamias, Athina Markou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eleni ThanouAnalysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, 15771 Athens, Greece.ORCID 0009-0003-5555-3630
Nikos Gavalas2nd Propaedeutic Department of Internal Medicine, Attikon University Hospital, National & Kapodistrian University of Athens, Chaidari, 12462 Athens, Greece.
Eleni KabraniLaboratory of Molecular Pathology, Department of General and Anatomic Pathology, Aristotle University School of Medicine, 54124 Thessaloniki, Greece.ORCID 0000-0003-0834-9912
Foteini Grigoriou2nd Propaedeutic Department of Internal Medicine, Attikon University Hospital, National & Kapodistrian University of Athens, Chaidari, 12462 Athens, Greece.
Anna Konstantinou2nd Propaedeutic Department of Internal Medicine, Attikon University Hospital, National & Kapodistrian University of Athens, Chaidari, 12462 Athens, Greece.
Vasiliki Malamatini2nd Propaedeutic Department of Internal Medicine, Attikon University Hospital, National & Kapodistrian University of Athens, Chaidari, 12462 Athens, Greece.
Christina Chourdaki Peristeri2nd Propaedeutic Department of Internal Medicine, Attikon University Hospital, National & Kapodistrian University of Athens, Chaidari, 12462 Athens, Greece.
Evi LianidouAnalysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, 15771 Athens, Greece.ORCID 0000-0002-7796-5914
Aristotelis Bamias2nd Propaedeutic Department of Internal Medicine, Attikon University Hospital, National & Kapodistrian University of Athens, Chaidari, 12462 Athens, Greece.ORCID 0000-0002-5996-7262
Athina MarkouAnalysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, 15771 Athens, Greece.ORCID 0000-0001-7760-9701

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFibroblast Growth Factor Receptor 3 (

methodsThe assay targeted four

resultsThe assay demonstrated clear cluster separation, no cross-reactivity, and reliable detection of all mutations down to 0.2% mutant allele frequency (MAF). Strong agreement was observed with a mutation-specific singleplex ddPCR assay for S249C. Concordance with NGS in tissue DNA was 74.2%, with ddPCR identifying additional low-abundance mutations not reported by NGS.

conclusionsThis ddPCR assay provides a rapid, sensitive, and cost-effective method for detecting clinically relevant

Indexed as

bladder cancerdrop-off ddPCRerdafitinibFGFR3 mutationsliquid biopsy

Identifiers

PMID42649945
PMCPMC13510398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.